SELLAS Life Sciences Group Inc (SLS)
1.33
-0.02
(-1.48%)
USD |
NASDAQ |
May 03, 16:00
1.315
-0.02
(-1.13%)
After-Hours: 20:00
SELLAS Life Sciences Group Research and Development Expense (Quarterly): 5.097M for Dec. 31, 2023
Research and Development Expense (Quarterly) Chart
Historical Research and Development Expense (Quarterly) Data
| Date | Value |
|---|---|
| December 31, 2023 | 5.097M |
| September 30, 2023 | 5.813M |
| June 30, 2023 | 5.923M |
| March 31, 2023 | 7.174M |
| December 31, 2022 | -4.154M |
| September 30, 2022 | 4.282M |
| June 30, 2022 | 5.529M |
| March 31, 2022 | 14.61M |
| December 31, 2021 | 3.393M |
| September 30, 2021 | 4.541M |
| June 30, 2021 | 3.456M |
| March 31, 2021 | 4.284M |
| December 31, 2020 | 2.771M |
| September 30, 2020 | 2.367M |
| June 30, 2020 | 2.28M |
| March 31, 2020 | 1.864M |
| December 31, 2019 | 2.246M |
| September 30, 2019 | 1.799M |
| June 30, 2019 | 1.381M |
| March 31, 2019 | 1.859M |
| December 31, 2018 | 3.651M |
| September 30, 2018 | 1.72M |
| June 30, 2018 | 1.592M |
| March 31, 2018 | 1.804M |
| December 31, 2017 | 0.71M |
| Date | Value |
|---|---|
| September 30, 2017 | 0.951M |
| June 30, 2017 | 1.827M |
| March 31, 2017 | 2.184M |
| December 31, 2016 | -3.847M |
| September 30, 2016 | 3.624M |
| June 30, 2016 | 6.175M |
| March 31, 2016 | 5.443M |
| December 31, 2015 | 4.849M |
| September 30, 2015 | 5.74M |
| June 30, 2015 | 7.197M |
| March 31, 2015 | 5.825M |
| December 31, 2014 | 6.211M |
| September 30, 2014 | 7.025M |
| June 30, 2014 | 8.069M |
| March 31, 2014 | 6.77M |
| December 31, 2013 | 6.434M |
| September 30, 2013 | 3.633M |
| June 30, 2013 | 5.276M |
| March 31, 2013 | 5.081M |
| December 31, 2012 | 4.061M |
| September 30, 2012 | 4.169M |
| June 30, 2012 | 3.72M |
| March 31, 2012 | 2.664M |
| December 31, 2011 | 2.094M |
| September 30, 2011 | 1.367M |
R&D Expense Definition
R&D expense is a line item from many companies' income statements.
Research and Development Expense (Quarterly) Range, Past 5 Years
-4.154M
Minimum
Dec 2022
14.61M
Maximum
Mar 2022
3.929M
Average
3.456M
Median
Jun 2021
Research and Development Expense (Quarterly) Benchmarks
| Geron Corp | 29.37M |
| Immuneering Corp | 11.91M |
| Protagonist Therapeutics Inc | 28.90M |
| Akebia Therapeutics Inc | 9.865M |
| Moderna Inc | 1.063B |